Bridge to Life Strengthens Position with VitaSmart Acquisition

Bridge to Life Ltd has made a strategic acquisition of the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from the Italian biomedical and MedTech company Medica S.p.A. The acquisition includes global branding and registration rights, strengthening Bridge to Life's position in organ preservation solutions. This move underscores Bridge to Life's commitment to advancing transplant medicine, potentially enhancing global access to transformational technology for organ transplant centers and ultimately benefiting patients awaiting viable organ transplants. The deal also aligns with Bridge to Life's objectives to expand its market reach and consolidate its portfolio with proven technologies. Medica S.p.A., having developed high-tech products for blood and water purification, will aid Bridge to Life in enriching its portfolio and enhancing its capabilities in transplant medicine. The company emphasizes quality, innovation, and accessibility, collaborating with leading transplant centers and organ procurement entities globally. Bridge to Life's CEO, Don Webber, highlighted that the company is close to completing FDA approval applications for the system, with plans to introduce it to the U.S. market in early 2025. This strategic acquisition is expected to enhance the company's market value and meet the global demand in the burgeoning organ preservation sector.